Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Discovery shows promise against severe side effects

05.11.2010
A team of scientists has found a way to eliminate a debilitating side effect associated with one of the main chemotherapy drugs used for treating colon cancer. The strategy used in their preclinical research—inhibiting an enzyme in bacteria of the digestive tract—could allow patients to receive higher and more effective doses of the drug, known as CPT-11 or Irinotecan.

The study, spearheaded by scientists at the University of North Carolina at Chapel Hill and involving collaborators at Albert Einstein College of Medicine of Yeshiva University and North Carolina Central University in Durham, is described in the November 5 issue of Science.

While the chemotherapy agent CPT-11 has proven useful in attacking colorectal tumors, it can also cause severe diarrhea - limiting the dosage that patients can tolerate and curbing the drug's potential effectiveness. The primary cause of the diarrhea is believed to be beta glucuronidase, an enzyme found in bacteria that live in the gastrointestinal tract.

After the liver has rendered CPT-11 inert, the drug enters the intestine where it's reactivated by the beta glucuronidase of the gut bacteria. The revived CPT-11 irritates the intestine and causes severe diarrhea in up to 30 percent of patients who receive it.

To overcome this crippling side effect, the UNC researchers decided to look for compounds that would block the action of beta glucuronidase without eliminating the gut bacteria, which are important for human health.

"We need to retain our intestinal bacteria – they help us digest food, make critical vitamins and protect us from infection," said Matthew R. Redinbo, Ph.D., who led the UNC research team, and is professor and chair of the chemistry department in the UNC College of Arts and Sciences and a member of the UNC Lineberger Comprehensive Cancer Center. "This targeted approach stops the one bacterial protein thought to cause the drug's devastating side effect, but without damaging the beneficial microbes or the intestines."

Study co-author, Sridhar Mani, M.D., professor of medicine and of genetics at Einstein, said the severe diarrhea caused by CPT-11 can sharply limit the dosage that cancer patients can receive. "Our tests showed conclusively that the inhibitor identified by our UNC colleagues prevented diarrhea in mice that were also receiving CPT-11. We're hopeful that clinical trials will show that administering this inhibitor when patients start taking CPT-11 allows for improvement in the drug's anti-tumor effect in patients with cancer."

The research was funded by the National Institutes of Health, the Golden Leaf Foundation and the State of North Carolina.

Other study co-authors were graduate students Bret D. Wallace and Jillian Orans, and postdoctoral fellow Kimberly T. Lane, Ph.D., all from the UNC chemistry department; Ja Seol Koo, M.D., and Christian Jobin, Ph.D., from the medicine department in the UNC School of Medicine; Hongwei Wang, Ph.D. and Madhukumar Venkatesh, Ph.D., from the departments of medicine, oncology and genetics at Albert Einstein College of Medicine; and John E. Scott, Ph.D., and Li-An Yeh, Ph.D., with the Biomanufacturing Research Institute and Technology Enterprise program at N.C. Central University.

UNC News Services contact:
Patric Lane,
(919) 962-8596,
patric_lane@unc.edu
Albert Einstein contact:
Kimberly Newman,
(718) 430-3101,
sciencenews@einstein.yu.edu
Mani online profile at
http://www.einstein.yu.edu/home/faculty/profile.asp?id=5615

Patric Lane | EurekAlert!
Further information:
http://www.unc.edu

More articles from Health and Medicine:

nachricht Millions through license revenues
27.04.2017 | Rheinische Friedrich-Wilhelms-Universität Bonn

nachricht New High-Performance Center Translational Medical Engineering
26.04.2017 | Fraunhofer ITEM

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Making lightweight construction suitable for series production

More and more automobile companies are focusing on body parts made of carbon fiber reinforced plastics (CFRP). However, manufacturing and repair costs must be further reduced in order to make CFRP more economical in use. Together with the Volkswagen AG and five other partners in the project HolQueSt 3D, the Laser Zentrum Hannover e.V. (LZH) has developed laser processes for the automatic trimming, drilling and repair of three-dimensional components.

Automated manufacturing processes are the basis for ultimately establishing the series production of CFRP components. In the project HolQueSt 3D, the LZH has...

Im Focus: Wonder material? Novel nanotube structure strengthens thin films for flexible electronics

Reflecting the structure of composites found in nature and the ancient world, researchers at the University of Illinois at Urbana-Champaign have synthesized thin carbon nanotube (CNT) textiles that exhibit both high electrical conductivity and a level of toughness that is about fifty times higher than copper films, currently used in electronics.

"The structural robustness of thin metal films has significant importance for the reliable operation of smart skin and flexible electronics including...

Im Focus: Deep inside Galaxy M87

The nearby, giant radio galaxy M87 hosts a supermassive black hole (BH) and is well-known for its bright jet dominating the spectrum over ten orders of magnitude in frequency. Due to its proximity, jet prominence, and the large black hole mass, M87 is the best laboratory for investigating the formation, acceleration, and collimation of relativistic jets. A research team led by Silke Britzen from the Max Planck Institute for Radio Astronomy in Bonn, Germany, has found strong indication for turbulent processes connecting the accretion disk and the jet of that galaxy providing insights into the longstanding problem of the origin of astrophysical jets.

Supermassive black holes form some of the most enigmatic phenomena in astrophysics. Their enormous energy output is supposed to be generated by the...

Im Focus: A Quantum Low Pass for Photons

Physicists in Garching observe novel quantum effect that limits the number of emitted photons.

The probability to find a certain number of photons inside a laser pulse usually corresponds to a classical distribution of independent events, the so-called...

Im Focus: Microprocessors based on a layer of just three atoms

Microprocessors based on atomically thin materials hold the promise of the evolution of traditional processors as well as new applications in the field of flexible electronics. Now, a TU Wien research team led by Thomas Müller has made a breakthrough in this field as part of an ongoing research project.

Two-dimensional materials, or 2D materials for short, are extremely versatile, although – or often more precisely because – they are made up of just one or a...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Fighting drug resistant tuberculosis – InfectoGnostics meets MYCO-NET² partners in Peru

28.04.2017 | Event News

Expert meeting “Health Business Connect” will connect international medical technology companies

20.04.2017 | Event News

Wenn der Computer das Gehirn austrickst

18.04.2017 | Event News

 
Latest News

Wireless power can drive tiny electronic devices in the GI tract

28.04.2017 | Medical Engineering

Ice cave in Transylvania yields window into region's past

28.04.2017 | Earth Sciences

Nose2Brain – Better Therapy for Multiple Sclerosis

28.04.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>